Supported by an educational grant from Quest Diagnostics
Over the last few years, a number of rapidly evolving new treatment options for chronic hepatitis C virus (HCV) infection have become available, including the emergence of new direct-acting antiviral agents (DAAs). Treatment with these DAAs—which include 3 NS3-4A protease inhibitors, 5 NS5A inhibitors, and 2 NS5B polymerase inhibitors in multiple combination regimens for the management of 6 HCV genotypes—has led to dramatic advances in terms of treatment efficacy, with sustained viral response (SVR) rates greater than 95% and minimal associated side effects. Although monitoring of clinical response and adverse events has been greatly simplified, many factors should be considered to determine the most appropriate DAA regimen, such as HCV genotype (including associated subtypes). Identifying genotype at baseline to differentiate treatment failure or re-infection has an important role. Assessment of liver fibrosis in HCV infection also is considered a relevant part of patient care and key for decision making.
Gastroenterologists, hepatologists, infectious disease specialists, internists, primary care clinicians, and other healthcare providers (HCPs) who treat patients with hepatitis C
After participating in this activity, clinicians should be better able to:
Select the appropriate direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection based on viral genotypes (and subtype) and associated complications
Identify the emergence of HCV resistance-associated variants (RAVs) following treatment with selected DAA regimens
Implement strategies, including the spectrum of molecular testing protocols, to identify and monitor disease progression and treatment efficacy and potentially avert HCV treatment resistance
Facilitate better linkage of care among specialists and other providers to strengthen screening, treatment, and monitoring practices, particularly for underserved and marginalized populations
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Rush University Medical Center Chicago, IL
Dr. Reau is a consultant for AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Merck & Co. She receives research funds from AbbVie Inc., Genfit SA, Shire, and TARGET PharmaSolutions.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Quest Diagnostics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.